PHARMACEUTICAL SOLVENTS MARKET ANALYSIS

Pharmaceutical Solvents Market Size and Trends

Pharmaceutical solvents market is estimated to be valued at USD 3.78 Bn in 2024 and is expected to reach USD 5.50 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031.

To learn more about this report, request sample copy

There is steady growth projected in the pharmaceutical solvents market over the forecast period. This is mainly attributed to rising pharmaceutical Research and Development (R&D) initiatives and increasing production of active pharmaceutical ingredients (APIs) across the globe. Additionally, growing generic and biopharmaceutical industry is further expected to drive the demand for various solvents such as ethyl acetate, isopropyl alcohol, and others. Also, changing lifestyle and increasing consumption of drugs for chronic diseases will boost market expansion from 2024 to 2031. However, stringent environmental regulations for certain pharmaceutical solvents may hinder the growth of the market during the forecast timeframe.

Market Driver - Increasing demand for pharmaceutical products globally

With the growing global population and rising healthcare needs, the demand for pharmaceutical products has increased tremendously over the past few decades. For instance, according to data by National Library of Medicine released in March , 2024, as of 2024, the global population is approximately 8.1 billion, having grown from 7.8 billion in mid-2020 and 7 billion in 2010. This growth reflects an annual increase of about 83 million, or 1.1% per year. Key factors driving this growth in demand include the aging population, rise of chronic and lifestyle-related diseases, improving access to medicines in developing markets, and growing affordability of drugs.

A much larger and aging global population means there are higher patients and cases of various illnesses that require medical treatment. Diseases related to old age such as cancer, cardiovascular conditions, and diabetes are on the rise worldwide. At the same time, lifestyle changes and lack of physical activity have led to sharp growth in cases of obesity, hypertension and other non-communicable diseases across both developed and developing nations.

Emerging economies with large populations, such as China, India, Brazil, and others, which were previously untapped markets are now opening up and people have greater economic ability to afford medicines. Governments in these countries have also invested heavily in expanding health insurance coverage. Coupled with growing incomes, this has enabled large sections of population to gain access to pharmaceutical treatments for the first time. Manufacturers have responded to this opportunity by setting up local manufacturing facilities, introducing low-cost generics as well as expanding their portfolio of drugs to address the disease patterns prevalent in developing regions.

Affordability of drugs has substantially improved in general due to enhanced price competition among manufacturers of both patented innovator drugs as well as low-cost generics. Companies regularly bring out cheaper biosimilar versions after patents of blockbuster drugs expire. Governments also play a role through initiatives like compulsory licensing to reduce medicine costs. Overall, there is a confluence of factors driving a steady rise in global demand for pharmaceutical products year after year, creating the need for higher production capacities and regular supply of various solvents used in drug manufacturing processes.

Growth in the biopharmaceutical sector

The biopharmaceutical industry has emerged as a major growth driver for the pharmaceutical sector and is witnessing rapid expansion worldwide. For instance, according to data released by Invest India in 2022, the pharmaceutical industry in India is expected to reach US$ 65 Bn by 2024 and to US$130 Bn by 2030. Biotech drugs also called biological or biologic drugs are mainly large, complex molecules manufactured in living systems such as microorganisms or animal cells. They include vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic proteins, monoclonal antibodies and others. These novel biotech therapies have revolutionized the treatment of various chronic, genetic, and life-threatening diseases.

Key factors fueling increased R&D and production of biotech drugs are the ability to target specific disease pathways more precisely, high efficacy demonstrated for cancers and other complex disorders, development of advanced bioprocess technologies, emergence of personalized medicine, blockbuster sales of flagship therapies, and expiry of patents on big biologics enabling production of biosimilars. Global sales figures point towards annual double-digit growth rates for biopharmaceuticals compared to low-single digit growth of conventional small molecule drugs. Big pharmaceutical companies are aggressively investing billions in the development of large pipelines of biological therapeutics in priority therapy areas as future blockbusters.

Manufacturing scale-up needs for these advanced biotech drugs are massive considering their production involves complex multi-step recombinant techniques, cell culture methods, and sophisticated purification technology. Multiple solvents are used at different stages for critical operations like fermentation, extraction, purification, and formulation. Given the difficulty and precision required to manufacture these highly sensitive large molecule drugs, their production cannot be ramped up without ensuring the availability of high purity solvents and efficiency of the various bioprocesses.